Salute e Benessere

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to…

Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy OfficerBoth executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025,...
Nasdaq GlobeNewswire
23/07/2025

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane…

New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments by way of co-optation of Dawn Svoronos and Jane Griffiths as Non-Executive Independent Directors to its Board of Directors, effective July 28, 2025. Dawn Svoronos and Jane Griffiths will replace Peter Guenter and Simon Sturge, who will step down from the Board on July 28, 2025...
Nasdaq GlobeNewswire
23/07/2025

Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter…

Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance pipeline expansionStrategic alternatives for the cell therapy business, including a potential divestiture, are being evaluated; CAR-T programs maintain positive momentum with recently presented clinical dataStrong balance sheet with €3.1 billion in cash and financial investments as of...
Nasdaq GlobeNewswire
23/07/2025

Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call…

Idorsia will publish its Half Year 2025 Financial Reporting on Wednesday July 30, at 07:00 CEST.An investor webcast and conference call will be held to discuss the results on the same day.Date: Wednesday, July 30, 2025 Time: 14:00 CEST / 13:00 BST / 08:00 EDT The call will start with presentations by senior management, including our new CEO Srishti Gupta, followed by a Q&A session. Live Webcast (audio + slides):The live webcast can be accessed from the Idorsia...
Nasdaq GlobeNewswire
23/07/2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – July 23, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 23, 2025, from Atlas Special…
Actusnews Wire
23/07/2025

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 5 convertible bonds in Oxurion resulting in a EUR 125,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market…
Actusnews Wire
23/07/2025

Blood Pressure Cuffs Market worth $1.3 billion in 2032 with 9.0% CAGR |…

Browse in-depth TOC on "Blood Pressure Cuffs Market" Browse in-depth TOC on "Blood Pressure Cuffs Market" 376 - Tables 50 - Figures 309 - Pages By type,the blood pressure cuffs market is divided into automated and manual segments. Appropriately validated automated blood pressure measuring devices (BPMDs) are considered the preferred standard for clinical diagnosis and management of hypertension. The growth of the automated segment is primarily fueled by the increasing...
PR Newswire
23/07/2025

Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins…

This transaction marks a key milestone in Croma-Pharma's international growth strategy and reinforces its commitment to providing scientifically validated, high-quality products for the global aesthetic market. This transaction marks a key milestone in Croma-Pharma's international growth strategy and reinforces its commitment to providing scientifically validated, high-quality products for the global aesthetic market. "We are thrilled to see Novaestiq join forces with Waldencast, a move…
PR Newswire
23/07/2025

Nuclear Medicine Software Market worth $1,491.55 million by 2030 with 9.0% CAGR…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212176442 Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212176442 Browse in-depth TOC on "Nuclear Medicine Software Market" 400 - Tables 120 - Figures 350 - Pages By application, the nuclear medicine software market has been segmented into diagnostic, therapeutics, emergency & stat workflows, and clinical research. Among these, the diagnostics...
PR Newswire
23/07/2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy…

While regulatory red tape tightens, surging diagnoses of colorectal and other GI cancers in young people demand quicker innovation in oncology. Forecasts suggest worldwide cancer‑drug revenues could blow past US$900 billion by 2034. Within that, next‑gen therapies built on precision techniques are slated to reach US$175.2 billion, advancing at a brisk 7.35% annual clip. While regulatory red tape tightens, surging diagnoses ofcolorectal and other GI cancersin young people demand quicker...
PR Newswire
23/07/2025

Seegene unveils the world's first unattended PCR automation, igniting a global…

CURECA™ is the world's first system to fully automate the entire PCR testing process – from specimen storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. Designed for 24/7 continuous operation, the system minimizes human error and dramatically improves the consistency and reliability of the test results. CURECA™ is the world's first system to fully automate the entire PCR testing process – from specimen storage and...
PR Newswire
23/07/2025

CeraVe Celebrates Two Decades of "Developed with Dermatologists" Skincare: A…

Over the past two decades, CeraVe has catapulted from a local US derm-backed secret to a global phenomenon, building an inclusive brand that appeals to all genders and generations. What remains unchanged is the brand's foundational insights: that most skin issues are linked to skin barrier disruption, and that skin identical ceramides are key to restoring and maintaining it. That insight began with three core products: Moisturizing Cream, Moisturizing Lotion and Hydrating Cleanser, and today…
PR Newswire
23/07/2025

Veeva OpenData and Veeva Network Enable Coordinated Customer Engagement for…

By consolidating its data strategy to one comprehensive solution, Boehringer Ingelheim is simplifying data management and building efficiencies. Standardization ensures fast access to consistent, high-quality customer data across teams and regions, and improves cross-team collaboration. Connected software and data from Veeva also streamlines Boehringer's migration to Veeva Vault CRM by leveraging native OpenData and Network integrations. By consolidating its data strategy to one comprehensive...
PR Newswire
23/07/2025

Singapore-Based Innovative Biomedical Start-Up Achieves 'Strategic Triumph' to…

With the product approval now achieved in China, labelled by German news platform 'Pressefeuer' a 'strategic triumph' that could revolutionize the world of biomedical engineering and is a decisive step for the Hanover-based company', Syntellix has achieved its most important strategic and operational goal. The strategic decision to develop the prioritized core markets of China, India, and ASEAN through Syntellix Asia Pte Ltd in Singapore, and to locate and expand the main production site in the…
PR Newswire
23/07/2025

Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure…

The findings mark a major advancement in the field of bioelectronic medicine for heart failure, highlighting the potential of the Cardio-Microcurrent (C-MIC) device—a novel implantable system that delivers low-intensity microcurrent to the failing myocardium. The findings mark a major advancement in the field of bioelectronic medicine for heart failure, highlighting the potential of the Cardio-Microcurrent (C-MIC) device—a novel implantable system that delivers low-intensity microcurrent to…
PR Newswire
23/07/2025

LenioBio secures EUR 3.7M of EU4Health funding to develop ALiCE® for…

This EU4Health action contributes to the European Union's strategic objective to strengthen the availability, accessibility, and affordability of essential medicines. By supporting the development of innovative manufacturing processes, HERA aims to enable more efficient, cost-effective, scalable, sustainable, and environmentally cleaner production of medicines. LenioBio will contribute with a project titled " Innovative protein medicine biomanufacturing with Continuous-Modular ALiCE...
PR Newswire
23/07/2025

Ipsen announces changes to its Executive Committee

PARIS, FRANCE, 23 July 2025 -Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:Mari Scheiffeleis appointed toEVP, Chief Product OfficerAndreas Gerberis appointed toEVP, Head of InternationalCaroline Sitbonis appointed toEVP, General Counsel Mari, Andreas and Caroline will report to Ipsen’s Chief Executive Officer, David Loew, beginning September 1, 2025.After 4...
Nasdaq GlobeNewswire
23/07/2025

Roche receives CE Mark for minimally invasive blood test to help rule out…

Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology.The minimally invasive, blood-based test can serve as a rule out for Alzheimer’s pathology, reducing the need for confirmatory testing with a negative result.Data from clinical study supports use in primary care for people with varying signs of cognitive decline. Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has...
Nasdaq GlobeNewswire
23/07/2025

European Commission approves Roche’s Itovebi for people with ER-positive…

Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone 1 Up to 40% of ER-positive breast cancers have a PIK3CA mutation and are associated with poor prognosis; this approval helps address an urgent unmet need 2-4 Itovebi is the first PI3K-targeted therapy to significantly extend survival, reinforcing the need for biomarker testing at diagnosis 5 Basel, 23 July 2025...
Nasdaq GlobeNewswire
23/07/2025

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to…

Key Takeaways from the ROR Inhibitors Market Report Key Takeaways from the ROR Inhibitors Market Report Discover which indication is expected to grab the major ROR inhibitors market share @ROR Inhibitors Market Report ROR Inhibitors Market Dynamics The RORs, particularly ROR1 and ROR2, have emerged aspromising druggable targetsin oncology and other diseases, driving the interest in ROR inhibitors. The ROR inhibitors market is currently in its nascent stages,...
PR Newswire
22/07/2025

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources…

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of James Briggs as its Chief Human Resources Officer, succeeding Caroline Daniere. An experienced human capital executive, James will lead key initiatives as DBV transitions from a development-stage biotechnology company to a potential commercial...
Nasdaq GlobeNewswire
22/07/2025

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5…

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations. About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives...
PR Newswire
22/07/2025

Global OTC Drug and Dietary Supplements Market Forecasts Indicate Significant…

This report provides a comprehensive analysis of the global market for OTC drugs, vitamins, and dietary supplements, focusing on pharmacological OTC products. The report highlights the trends, and challenges shaping the market, along with recent product launches, mergers and acquisitions, and collaborations. It offers insights into the competitive landscape, including the market shares and profiles of leading companies. Alternative therapies and certain supplement categories like weight…
PR Newswire
22/07/2025

Roche’s Board of Directors proposes exchange of Genussscheine for participation…

Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will replace the non-voting equity securities (Genussscheine). Reduction of the nominal value of the bearer shares (Inhaberaktien) from CHF 1 to CHF 0.001 in line with the nominal value of the new participation certificates.Participation certificates are economically equivalent to Genussscheine and will be listed on the SIX Swiss Exchange.Discontinuation of printed dividend vouchers and a...
Nasdaq GlobeNewswire
22/07/2025
Altri  Comunicati